Martin Nicklasson
Chairman of the Board of Directors
Orexo
Sweden
Biography
CEO at Swedish Orphan Biovitrum AB 2007–2010. Astra/AstraZeneca 1978–1989 and 1991–2007, e.g. responsible for global drug development and marketing and business development within AstraZeneca Ltd., and CEO of AstraZeneca Sweden AB, CEO of Astra Hässle AB and responsible for R&D within KABI. Holds 10,000 shares and stock options entitled to 162,916 shares, as of December 31 2016.
Research Interest
Business management
